公开(公告)号：KR1020110093427A

公开(公告)日：2011-08-18

申请号：KR1020100013470

申请日：2010-02-12

Applicant: 서울대학교산학협력단

Inventor： 성승용 ,  조남혁 ,  최신규 ,  장숙희 ,  원해영 ,  나혜영 ,  문혜정 ,  조성은

IPC: C07K16/18 ,  C12N15/63 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/3092

Abstract: PURPOSE: A single domain antibody or nanoscale antibody or nanoMAb is provided to diagnose cancer tissue which expresses MUC1 and to be used as an anti-tumor target therapeutic agent. CONSTITUTION: A single domain antibody for MUC1 contains a heavy chain variable region having: CDR1 selected from the group consisting of amino acids of sequence numbers 24-30; CDR2 selected from the group consisting of amino acids of sequence numbers 31-37; or CDR3 selected from the group consisting of amino acid of sequence number 38-44. The single domain antibody additionally contains a functional molecule. The functional molecule is chemicals, peptides, polypeptides, nucleic acids, carbohydrate, lipid, or inorganic particles.

Abstract translation: 目的：提供单域抗体或纳米抗体或纳米抗体，以诊断表达MUC1的癌组织，并用作抗肿瘤靶标治疗剂。 构成：用于MUC1的单结构域抗体包含重链可变区，其具有：CDR1，其选自序列号24-30的氨基酸; CDR2选自序列号31-37的氨基酸; 或选自序列号38-44的氨基酸的CDR3。 单结构域抗体另外含有功能性分子。 功能分子是化学物质，肽，多肽，核酸，碳水化合物，脂质或无机颗粒。

公开(公告)号：KR1020110063154A

公开(公告)日：2011-06-10

申请号：KR1020090120104

申请日：2009-12-04

Applicant: 서울대학교산학협력단

Inventor： 성승용 ,  양휘 ,  조남혁 ,  최신규 ,  장숙희 ,  문혜정 ,  배민영 ,  김태주 ,  조성은 ,  김영주

IPC: C07K19/00 ,  C07K14/35 ,  C07K14/155 ,  A61K39/00

Abstract: PURPOSE: A fusion antigen and a method for manufacturing a mature dendritic cell vaccine for immunotherapy using the same are provided to improve efficiency. CONSTITUTION: A fusion antigen used in manufacturing dendritic cell vaccine for immunotherapy contains PTD-MUC1 fusion protein containing MUC1(mucin antigen 1) fused to protein transduction domain(PTD) or PTD-Ag85A fusion protein. The fusion antigen is PTD-MUC1-Ag85A or PTD-Ag85A-MUC1. A method for manufacturing the dendritic cell vaccine comprises: a step of preparing immature dendritic cells; and a step of culturing the cells with the fusion antigen for maturing the cells. A pharmaceutical composition for anticancer immunotherapy contains pharmaceutically effective amount of the dendritic cell vaccine and pharmaceutically acceptable carrier.

Abstract translation: 目的：提供融合抗原和使用其制备用于免疫治疗的成熟树突状细胞疫苗的方法以提高效率。 构成：用于制备用于免疫治疗的树突状细胞疫苗的融合抗原包含与蛋白转导结构域（PTD）或PTD-Ag85A融合蛋白融合的含有MUC1（粘蛋白抗原1）的PTD-MUC1融合蛋白。 融合抗原为PTD-MUC1-Ag85A或PTD-Ag85A-MUC1。 树突细胞疫苗的制造方法包括：制备未成熟树突状细胞的步骤; 以及用于使细胞成熟的融合抗原培养细胞的步骤。 用于抗癌免疫疗法的药物组合物含有药学有效量的树突状细胞疫苗和药学上可接受的载体。